REAL-WORLD USAGE OF BORTEZOMIB IN COMBINATION WITH THALIDOMIDE AND DEXAMETHASONE (VTD) AS FRONTLINE (FL) TREATMENT IN STEM CELL TRANSPLANT (SCT) ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS ACROSS EU5 COUNTRIES

被引：0
|
作者：
Anjo, J. [1 ]
Rider, A. [2 ]
Bailey, A. [2 ]
Gaudig, M. [3 ]
机构：
[1] Janssen, Porto Salvo, Portugal
[2] Adelphi Real World, Manchester, Lancs, England
[3] Hlth Econ & Market Access Janssen EMEA, Neuss, Germany
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.414
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN332
引用
收藏
页码：S70 / S70
页数：1
相关论文
共 39 条
  • [1] REAL-WORLD USAGE OF BORTEZOMIB IN COMBINATION WITH MELPHALAN AND PREDNISONE (VMP) AS FRONTLINE (FL) TREATMENT IN STEM CELL TRANSPLANT (SCT) INELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS ACROSS EU5 COUNTRIES
    Anjo, J.
    Rider, A.
    Gaudig, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S72 - S72
  • [2] Real-World Data on Frontline (FL) Treatments in Multiple Myeloma (MM) Patients across EU5 Countries
    Anjo, Joana
    Rider, Alex
    Bailey, Abigail
    Gaudig, Maren
    [J]. BLOOD, 2018, 132
  • [3] Bortezomib, Thalidomide and Dexamethasone Compared to Cyclophosphamide, Bortezomib and Dexamethasone As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma: Real World Experience with Multiple Myeloma Patients in Colombia
    Cesar Solano, Julio
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S248 - S248
  • [4] Bortezomib-Thalidomide-Dexamethasone (VTD) As Salvage Treatment in Patients with Multiple Myeloma Candidates for Transplantation in the Real World
    Vasquez, Jule
    Quintana, Shirley
    Lopez, Lourdes
    Alcarraz, Cindy
    Villena, Marco
    Neciosup, Silvia
    Mas, Luis
    Gomez, Henry
    [J]. BLOOD, 2017, 130
  • [5] An Adjusted Treatment Comparison of Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Thalidomide/Dexamethasone from Real-World Data in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible
    Mehra, Maneesha
    Cote, Sarah
    Kampfenkel, Tobias
    Nair, Sandhya
    [J]. BLOOD, 2019, 134
  • [6] Bortezomib-Thalidomide-Dexamethasone (VTD) as salvage treatment in patients with Multiple Myeloma eligible for transplantation in the real world. Long-term follow-up.
    Vasquez, Jule
    Quintana, Shirley
    Alcarraz, Cindy
    Villena, Marco
    Vidaurre, Tatiana
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S162 - S163
  • [7] Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients
    Shuichiro Takashima
    Toshihiro Miyamoto
    Masanori Kadowaki
    Yoshikiyo Ito
    Takatoshi Aoki
    Ken Takase
    Takahiro Shima
    Goichi Yoshimoto
    Koji Kato
    Tsuyoshi Muta
    Motoaki Shiratsuchi
    Katsuto Takenaka
    Hiromi Iwasaki
    Takanori Teshima
    Tomohiko Kamimura
    Koichi Akashi
    [J]. International Journal of Hematology, 2014, 100 : 159 - 164
  • [8] Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients
    Takashima, Shuichiro
    Miyamoto, Toshihiro
    Kadowaki, Masanori
    Ito, Yoshikiyo
    Aoki, Takatoshi
    Takase, Ken
    Shima, Takahiro
    Yoshimoto, Goichi
    Kato, Koji
    Muta, Tsuyoshi
    Shiratsuchi, Motoaki
    Takenaka, Katsuto
    Iwasaki, Hiromi
    Teshima, Takanori
    Kamimura, Tomohiko
    Akashi, Koichi
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 100 (02) : 159 - 164
  • [9] Canadian Retrospective Multicentric Study Comparing the Combination of Bortezomib, Cyclophosphamide and Dexamethasone (Cybord) Versus Bortezomib, Thalidomide and Dexamethasone (VTD) Versus Bortezomib and Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma Eligible for Autologous Hematopoietic Stem Cell Transplantation (HCT)
    Yamga, Eric
    Leblanc, Richard
    Boudreault, Jean-Samuel
    [J]. BLOOD, 2018, 132
  • [10] Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Multiple
    Schutz, Natalia P.
    Ochoa, Paola
    Duarte, Patricio
    Remaggi, Guillermina
    Yantorno, Sebastian
    Corzo, Ariel
    Zabaljauregui, Soledad
    Shanley, Claudia
    Lopresti, Sergio
    Orlando, Sergio
    Verri, Veronica
    Quiroga, Luis
    Garcia, Carlos A.
    Fernandez, Vanesa
    Fantl, Dorotea
    [J]. HEMATOLOGICAL ONCOLOGY, 2020, 38 (03) : 363 - 371
1234